05/15/2025
7:38 AM | Context Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
| Form SCHEDULE 13G/A | |
05/09/2025
12:08 PM | Context Therapeutics (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G/A | |
04/09/2025
6:33 AM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/20/2025
3:44 PM | Context Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/28/2025
3:06 PM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2025
9:02 AM | Avidity Partners Management LP (Filed by)
Context Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
02/14/2025
5:27 AM | Context Therapeutics (Subject)
Opaleye Management Inc. (Filed by)
| Form SCHEDULE 13G/A | |
02/12/2025
4:20 PM | Context Therapeutics (Subject)
Lehr Martin A. (Filed by)
| Form SCHEDULE 13G/A | |
01/27/2025
11:55 AM | Context Therapeutics (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G | |
01/14/2025
7:36 PM | Context Therapeutics (Issuer)
Pasternak Andy (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/14/2025
7:43 PM | Context Therapeutics (Issuer)
Pasternak Andy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for CNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
01/14/2025
4:03 PM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/13/2025
6:37 AM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/08/2025
3:07 PM | Context Therapeutics (Subject)
MPM BioImpact LLC (Filed by)
| Form SCHEDULE 13G | |
12/23/2024
8:26 AM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/02/2024
3:20 PM | Context Therapeutics (Filer)
| Form 424B5 | |
12/02/2024
3:21 PM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
11:15 PM | Context Therapeutics (Filer)
| Form EFFECT | |
11/14/2024
3:52 PM | Context Therapeutics (Subject)
GREAT POINT PARTNERS LLC (Filed by)
| Form SC 13G/A | |
11/06/2024
4:08 PM | Context Therapeutics (Subject)
Hudson Bay Capital Management LP (Filed by)
| Form SC 13G/A | |
11/06/2024
3:42 PM | Context Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
09/23/2024
6:33 AM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/17/2024
3:22 PM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/05/2024
7:15 AM | Context Therapeutics (Issuer)
Smith Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
7:01 AM | Context Therapeutics (Issuer)
Walker Luke Nathaniel (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/05/2024
7:04 AM | Context Therapeutics (Issuer)
Walker Luke Nathaniel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
7:08 AM | Context Therapeutics (Issuer)
Smith Karen L. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/04/2024
6:34 AM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/01/2024
4:15 PM | Context Therapeutics (Issuer)
Dansky Ullmann Claudio (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
08/01/2024
4:18 PM | Context Therapeutics (Issuer)
Dansky Ullmann Claudio (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/24/2024
4:07 PM | Context Therapeutics (Filer)
| Form DEFA14A | |
07/24/2024
3:55 PM | Context Therapeutics (Filer)
| Form DEF 14A | |
07/10/2024
6:33 AM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/14/2024
6:52 AM | Context Therapeutics (Issuer)
Stacey Jennifer Evans (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2024
6:41 AM | BERMAN RICHARD J (Reporting)
Context Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2024
6:47 AM | Context Therapeutics (Issuer)
West Linda (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2024
6:50 AM | Context Therapeutics (Issuer)
Kantoff Philip W. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2024
6:34 AM | Context Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/05/2024
9:45 AM | Context Therapeutics (Subject)
GREAT POINT PARTNERS LLC (Filed by)
| Form SC 13G | |
06/02/2024
11:15 PM | Context Therapeutics (Filer)
| Form EFFECT | |
05/24/2024
6:31 AM | Context Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad) Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade.
In 2023, it surged 239%. And in 2024, it soared another 171% on the year…
But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less? Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. |
Buy CNTX Stock Free CNTX Stock Alerts